Women living in homes with elevated radon levels have higher odds of developing ovarian cancer, researchers reported April 10 in JAMA Network Open. “The risks of ovarian cancer, particularly serous ...
PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant ...
A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) ...
A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s ...
The phase 1 BEHOLD-1 trial of B7-H4-directed mocertatug rezetecan (Mo-Rez, formerly HS-20093) showed an objective response rate (ORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in ...
Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited ...
Ovarian cancer is the most lethal malignancy of the female reproductive system. Due to its insidious early symptoms and the ...
In today’s Health Alert, an invisible gas in your home could be raising cancer risk in women. New research links radon ...
Media ReleaseCOPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in ...
The data from AbbVie’s PICCOLO trial were presented at the SGO meeting 2026.
NRG-GY019 backs current LGSOC standard care; endocrine therapy alone promising in some pat ...
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug ...